Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • EGb 761 for dementia with neuropsychiatric symptoms

A recently published review demonstrates the efficacy of the plant extract

    • Neurology
    • News
    • Pharmacology and toxicology
    • RX
  • 5 minute read

The present review represents an analysis of four studies published between 2007 and 2012 that investigated the efficacy of the Ginkgo biloba extract EGb 761 in patients with age-related dementia associated with neuropsychiatric symptoms versus placebo and, in one case, versus the cholinesterase inhibitor donepezil or the combination of EGb 761 plus donepezil.

Thanks to its neuroprotective properties, the standardized extract EGb 761 obtained from leaves of the tree Ginkgo biloba is effective against various pathomechanisms of dementia [1]. For example, it improves mitochondrial functions [2,3], capillary blood flow [4] and neurogenesis at risk in the hippocampus [5,6], among others.

The efficacy of EGb 761 in both Alzheimer’s type dementia (AD) and vascular dementia (VaD) and mixed forms has been documented with several double-blind randomized controlled clinical trials. Recent studies and meta-analyses have demonstrated efficacy in cognitive function and activities of daily living. This reduced caregiver burden, although improvements were moderate and heterogeneous, as is the case with other anti-dementia agents [7–9].

Certain studies indicate that EGb 761 improves not only cognitive functions but also neuropsychiatric symptoms, and that patients with problems in daily living activities respond better to therapy than those suffering exclusively from cognitive disorders [10,11].

As a daily dose, 240 mg was shown to be more effective than 120 mg [8]. EGb 761 proved to be very well tolerated, and ADRs were comparable in number and severity to placebo [7–9,12]. Although there were also studies with a negative result [12], the treatment of dementia with EGb 761 was included in the guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP).

To examine whether more recent studies confirm this recommendation, four recent studies of elderly patients with Alzheimer-type dementia, vascular dementia, or mixed-form dementia who also had neuropsychiatric symptoms and had problems with activities of daily living were reviewed.

Method

The four studies were published between 2007 and 2012. Table 1 provides information on the number of subjects, diagnosis, duration of the study, treatment, and primary and secondary outcome variables.

The studies show a consistent picture in terms of duration, inclusion criteria, treatment, and evaluation. Three studies evaluated the efficacy of EGb 761 versus placebo, and one study was conducted as a three-arm comparative study comparing the efficacy of EGb 761 with donepezil and with EGb 761 plus donepezil. In the four studies, subjects did not differ significantly with respect to demographic criteria or baseline values of the parameters collected.

 

Results

All values collected were statistically analyzed.In the three studies EGb 761 vs. placebo, significant improvement was found for the Ginkgo biloba groups with respect to both cognitive impairment (SKT) and neuropsychiatric problems (NPI) compared to placebo. This was evident both in terms of absolute improvement and in terms of the number of patients in whom the improvement was at least three points for the SKT and at least four points for the NPI.

Secondary outcome variables, except for tinnitus in the study by Herrschaft et al. [15], consistently significant improvements were found for the verum groups for EGb 761, especially also for activities of daily living (ADL). In the three-arm comparative study of EGb 761 versus donepezil or EGb 761 plus donepezil, SKT, NPI, and NPI nurses showed a slight superiority of donepezil over EGb 761 in terms of improvement in measures, whereas in terms of the other parameters collected, EGb 761 showed greater improvement than donepezil. The combination of Ginkgo biloba with the cholinesterase inhibitor proved superior to the two single substances in all parameters. However, none of these values in the three-arm study showed significance.

Discussion

The results evaluated in these four studies confirm the findings of previous studies. Ginkgo biloba extract EGb 761 improves cognitive function and neuropsychiatric symptoms in patients with related conditions. With respect to everyday tasks, previous studies have not shown superiority of EGb 761. The present study also confirmed improvement in daily living activities in patients with cognitive impairment and neuropsychiatric problems. A significant improvement was also observed in the accompanying symptoms of tinnitus and dizziness with EGb 761.

Because approximately 80% of all patients with dementia also have neuropsychiatric problems [17], the present studies are more practically designed than many other studies.

Conclusion

The present study shows that daily administration of 240 mg of the herbal extract EGb 761 improves cognitive and neuropsychiatric symptoms in patients with age-related dementia in a manner comparable to cholinesterase inhibitors and also leads to improvement in daily activities. Therefore, EGb 761 is suitable for the treatment of corresponding patients.

Source: Ihl R: Effects of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features; review of recently completed randomised, controlled trials. Int J Psychiatriy Clin Pract 2013; Early Online: DOI:10:3109/13651501.2013.814796.

Literature:

  1. Ramassamy C, Longpre F, Christen Y: Ginkgo biloba extract (EGb 761) in Alzheimer’s disease: is there any evidence? Curr Alzheimer Res 2007; 4: 253-262.
  2. Abdel-Kader R, et al: Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007; 56: 493-502.
  3. Eckert A, et al: Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 2003; 36: S15-S23.
  4. Költringer P, Langsteger W, Eber O: Dosedependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 1995; 15: 649-656.
  5. Bastianetto S, Zheng WH, Quirion R: The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J Neurochem 2000; 74: 2268-2277.
  6. Tchantchou F, et al: EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 2000: 21: 2400-2408.
  7. Ernst E, Pittler MH: Ginkgo biloba for vascular dementia and Alzheimer’s disease: updated systematic review of double-blind, placebo-controlled, randomized trials. Perfusion 2005; 18: 388-392.
  8. Janssen IM, et al: Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 2010; 160: 539-546.
  9. Weinmann S, et al: Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010; 10: 14.
  10. Hoerr R: Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 2003; 36: S56-S61.
  11. Schneider LS, et al: A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005; 2: 541-551.
  12. Birks J, Grimley Evans J: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; (1): CD003120.
  13. Napryeyenko O, Borzenko I: Ginkgo bilobaspecial extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Drug Research 2007; 57: 4-11.
  14. Ihl R, et al: Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 2010; 26: 1186-1194.
  15. Herrschaft H, et al: Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 2012; 46: 716-723.
  16. Yancheva S, et al: Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 2009; 13: 183-190.
  17. Steinberg M, et al: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23: 170-177.

HAUSARZT PRAXIS 2014; 9(10): 7-8

Autoren
  • Dr. pharm. Christoph Bachmann
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • Dementia
  • egb 761
  • neuropsychiatric symptoms
Previous Article
  • Glioblastoma and brain metastases

Immune system can be harnessed

  • Congress Reports
  • Oncology
  • RX
  • Studies
View Post
Next Article
  • Guidelines at the ESC Congress 2014

What is different, what is new?

  • Cardiology
  • Congress Reports
  • Pneumology
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.